Induced pluripotent stem cell-derived mesenchymal stem cells for modeling and treating metabolic associated fatty liver disease and metabolic associated steatohepatitis: challenges and opportunities

Marques da Silva, Barbara Sofia; Bragança, José

http://hdl.handle.net/10400.1/26954

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
WJSC-17-99331.pdf		995.32 KB	Adobe PDF	Download

Send Feedback

Authors

Marques da Silva, Barbara Sofia

Bragança, José

Abstract(s)

The potential of induced pluripotent stem cells (iPSCs) for modeling and treating metabolic associated fatty liver disease (MAFLD) and metabolic associated steatohepatitis (MASH) is emerging. MAFLD is a growing global health concern, currently with limited treatment options. While primary mesenchymal stem cells hold promise, iPSCs offer a versatile alternative due to their ability to differentiate into various cell types, including iPSC-derived mesenchymal stem cells. However, challenges remain, including optimizing differentiation protocols, ensuring cell safety, and addressing potential tumorigenicity risks. In addition, iPSCs offer the possibility to generate complex cellular models, including three-dimensional organoid models, which are closer representations of the human disease than animal models. Those models would also be valuable for drug discovery and personalized medicine approaches. Overall, iPSCs and their derivatives offer new perspectives for advancing MAFLD/MASH research and developing novel therapeutic strategies. Further research is needed to overcome current limitations and translate this potential into effective clinical applications.

Keywords

Metabolic associated fatty liver disease Metabolic associated steatohepatitis Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis Mesenchymal stem cells Induced pluripotent stem cells In vitro liver models